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Background: Structural and functional brain imaging studies suggest abnormalities of the amygdala and hippocampus in posttraumatic
stress disorder and major depressive disorder. However, structural brain imaging studies in social phobia are lacking. Methods: In total, 
24 patients with generalized social phobia (GSP) and 24 healthy controls underwent 3-dimensional structural magnetic resonance imaging
of the amygdala and hippocampus and a clinical investigation. Results: Compared with controls, GSP patients had significantly reduced
amygdalar (13%) and hippocampal (8%) size. The reduction in the size of the amygdala was statistically significant for men but not women.
Smaller right-sided hippocampal volumes of GSP patients were significantly related to stronger disorder severity. Limitations: Our sample
included only patients with the generalized subtype of social phobia. Because we excluded patients with comorbid depression, our sample
may not be representative. Conclusion: We report for the first time volumetric results in patients with GSP. Future assessment of these pa-
tients will clarify whether these changes are reversed after successful treatment and whether they predict treatment response.
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Introduction
Present evidence from functional brain imaging studies sug-
gests that patients with social phobia, posttraumatic stress dis-
order (PTSD) or specific phobia share a pattern of hyperactivity
of the amygdala and surrounding cortices, including the hip-
pocampus, linked to negative emotional responses.1 The major-
ity of studies including patients with social phobia suggest that
these changes may be most pronounced in the generalized sub-
type of social phobia (GSP).2–4 A recent study suggests that
these changes may resolve after successful psychotherapeutic
or psychopharmacologic treatment of social phobia.5
There is now an extensive body of evidence suggesting
that PTSD6 and major depressive disorder7,8 are related to ab-
normal amygdalar and hippocampal size. However, the
mechanisms underlying these changes are not well under-
stood. Research in nonhuman primates has suggested that
stress and prolonged glucocorticoid exposure may damage
the hippocampus,9 thus raising the possibility that stress may
also induce hippocampal degeneration in humans with anxi-
ety or affective disorders. Another possibility is that pre-
existing small hippocampal size increases the risk for de -
veloping anxiety or affective disorders.10,11
However, structural brain imaging studies in social phobia
are lacking. Given the fact that patients with traumatic and
nontraumatic anxiety disorders share a pattern of medial
temporal hyperactivity during functional neuroimaging,1
investigation into structural aspects of the amygdala and hip-
pocampus in social phobia are warranted. Furthermore, be-
cause the more severe form of social phobia (i.e., GSP) is
likely associated with continuous and extreme stress, the pos-
sibility of a reduction of the size of the amygdala and hip-
pocampus is likely.
We investigated amygdala and hippocampal volumes in
adults with GSP and healthy controls. The goals of our study
were to investigate whether amygdalar and hippocampal size
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are reduced in individuals with GSP, to investigate whether
these changes are more pronounced in individuals with
stronger disorder severity and to explore how specific clinical
symptoms are related to amygdalar and hippocampal size.
We expected that individuals with GSP would have re-
duced amygdalar and hippocampal size. We hypothesized
that stronger clinical symptoms in GSP patients would be re-
lated to smaller amygdalar and hippocampal size.
Methods
Participants
We included outpatients with GSP, admitted to the clinic of
the Department of Psychosomatics and Psychotherapy of the
University of Göttingen, Germany. The patients were re-
cruited as part of a multicentre randomized controlled trial of
psychotherapy for social phobia (pretreatment assessment)12
(www.controlled-trials.com/ISRCTN53517394).
Our inclusion criterion were age 18–70 years with a diagno-
sis of social phobia (DSM-IV) and a score on the Liebowitz 
Social Anxiety Scale (LSAS) greater than 30.13 We included
only patients whose primary diagnosis was social phobia (i.e.,
the most severe disorder according to the Anxiety Disorders
Interview Schedule Adult Version [ADIS-IV] rating14). We ex-
cluded patients with a history of neurologic disease, severe
medical conditions, psychotic and affective disorders, prom -
in ent risk of self-harm, current substance-related disorders,
PTSD, traumatic exposure or personality disorders except for
avoidant personality disorder (APD) (as assessed by the
Structured Clinical Interview for DSM-IV Axis II Personality
Disorders [SCID-II]15). We excluded patients receiving concur-
rent psychotherapeutic or psychopharmacologic treatment. 
We compared GSP patients with healthy controls matched
for sex, age, height and years of education. We recruited con-
trols through an advertisement in a local newspaper and
leaflets distributed at the Hospital of the University of Göttin-
gen and in town. We included only individuals without a
history of neurologic or psychiatric disorders (as assessed by
SCID-I16 and SCID-II15).
We obtained written informed consent from all partici-
pants after providing them with a complete description of the
study. The ethical committee of the medical faculty of the
University of Göttingen approved the study design.
Clinical assessment
An experienced and trained interviewer (U.S.-B.) performed
the diagnosis using SCID-I and SCID-II.15,16 We verified the
diag nosis of GSP by use of SCID-I with additional probes
from the LSAS17 (i.e., when more than 12 fears were present).
Subscales of the LSAS were defined according to Heimberg
and colleagues.18 We further assessed clinical symptoms by
the Social Phobia and Anxiety Inventory (SPAI)19 and the State
Trait Anxiety Inventory (STAI).20 We assessed depressive
symptoms by use of the Beck Depression Inventory (BDI).21
We carefully screened all participants for traumatic exposure
by use of the SCID-I and the Early Trauma Inventory–Short
Form,22 because amygdala and hippocampal size have been
shown to be diminished in patients with PTSD.6
Magnetic resonance imaging assessment
We obtained images using a 3-T magnetic resonance imaging
(MRI) scanner (MAGNETOM Trio; Siemens Healthcare). Par -
ameters of the T1-weighted 3-dimensional (3-D) sequence at
1 mm isotropic resolution were as follows: echo time 2.6 ms;
repetition time 2250 ms; inversion time 900 ms; flip angle 9°;
field-of-view 256; slice plane sagittal; matrix 256 × 256; slice
thickness 1.0 mm; and 176 slices. We performed volumetric
analysis on the basis of 3-D MRI scans. We transferred the
images to a computer workstation and processed them using
CURRY software, version 4.5 (Neurosoft Inc.).
We calculated intracranial volume and total brain volume
with automated multistep algorithms and 3-D region grow-
ing methods limited by grey value thresholds. Simultaneous
3-D visualization of brain structures and manual tracing al-
lowed a precise identification and delineation of the regions
of interest. We separately disarticulated the amygdala and
hippocampus from the surrounding tissue on coronal slices
by means of manual tracing according to a standardized pro-
tocol.23 We separated the amygdala and hippocampus by 3-D
visualization of the alveus and the inferior horn of the lateral
ventricle. The anterior border of the hippocampus was found
on the coronal slice showing the alveus and/or the uncal re-
cess of the inferior horn of the lateral ventricle, and the pos -
ter ior border was found on the slice where an ovoid mass of
grey matter appeared inferiomedially to the trigone of the lat-
eral ventricle. 
A single rater (C.L.), who was unaware of the diagnosis,
performed the assessment. To define intrarater reliability, the
analyst reassessed 1 hemisphere of 10 randomly chosen
cases. The intraclass correlation coefficients for this proce-
dure were r = 0.94 for the amygdala and r = 0.95 for the hip-
pocampus. Interrater reliabilities, including that of this rater,
have been published previously (hippocampus: r = 0.96;
amygdala: r = 0.96).24,25
Statistical analysis
We used t tests to compare differences between groups for
demographic and clinical variables and for intracranial and
total brain volume. We compared amygdalar and hippocam-
pal volumes of GSP patients and the control group using
analyses of covariance (ANCOVA) with group and sex as the
between-subjects factors and hemisphere as the within-
subjects factor and with adjustment for total brain volume.
We used multiple stepwise regression analyses with a signifi-
cance level for selecting variables of α = 0.05 to examine the
relations between amygdalar and hippocampal volumes and
clinical variables. We used left- and right-sided amygdalar
and hippocampal volumes and total brain volume as ex-
planatory variables and clinical scores as dependent vari-
ables. All analyses were 2-tailed; we set the level of statistical
significance at p < 0.05. We corrected the results of clinical in-
struments for multiple testing (Bonferroni correction: α level
for the LSAS = 0.016). We performed statistical analyses 




Our sample comprised 24 outpatients with GSP and 24
healthy matched controls. Participant characteristics are pro-
vided in Table 1. Four GSP patients had a history of psy-
chotherapeutic treatment (18, 3, 1 or 1/2 years) before the
present assessment. Four patients had a history of psy-
chopharmacologic treatment. Three had received antidepres-
sant drugs about 10 years before the present assessment; 
1 patient was irregularly taking benzodiazepines 2 years be-
fore the present assessment. 
The male (n = 12) and female (n = 12) GSP patients did not
differ significantly in terms of age, education, age at disorder 
onset, disorder duration or for any of the clinical variable in
Table 1. Comorbid diagnoses and clinical measures for all GSP
patients are summarized in Table 1. Results from the SCID-I and
the Early Trauma Inventory–Short Form revealed that none of
the GSP patients or control participants experienced childhood
physical or sexual abuse or other traumatic exposure.
Brain measures: group comparisons
An overall 2 × 2 × 2 (group × sex × hemisphere) ANCOVA
comparing the amygdalar volumes of GSP patients and con-
trols and adjusting for total brain volume yielded a signifi-
cant effect of group, indicating that GSP patients had smaller
amygdalar volumes than controls (Table 2). The group × sex
interaction was also significant, indicating stronger amyg-
dalar size reduction in men than in women in the GSP group.
The following F values were obtained: group, F1,43 = 11.46,
p = 0.002; sex, F1,43 = 0.14, p = 0.71; hemisphere, F1,43 = 0.03,
p = 0.87; group × hemisphere, F1,43 = 1.43, p = 0.24; group ×
sex, F1,43 = 9.77, p = 0.003; sex × hemisphere, F1,43 = 0.38,
p = 0.54; group × sex × hemisphere, F1,43 = 0.04, p = 0.85. 
The posthoc 2 × 2 (group × sex) ANCOVA adjusting for to-
tal brain volume confirmed these results for the left and right
amygdala. The following F values were obtained for the left
amygdala: group, F1,43 = 13.29, p = 0.001; sex, F1,43 = 0.48,
p = 0.49; group × sex, F1,43 = 6.80, p = 0.012. The values for the
right amygdala were as follows: group, F1,43 = 4.20, p = 0.046;
sex, F1,43 = 0.00, p = 0.98; group × sex, F1,43 = 6.68, p = 0.013. The
posthoc 1-way ANCOVA revealed that male GSP patients
had smaller left (F1,21 = 12.89, p = 0.002) and right (F1,21 = 13.33,
p = 0.001) amygdalar volumes compared with male controls.
However, female GSP patients did not differ significantly
from female controls.
The overall 2 × 2 × 2 (group × sex × hemisphere) AN-
COVA comparing the hippocampal volumes of GSP patients
and controls and adjusting for total brain volume yielded a
significant effect of group, indicating that GSP patients had
smaller hippocampal volumes than controls (Table 2). The
sex × hemisphere interaction was also significant, indicating a
stronger left–right asymmetry in women (right hippocampus
> left hippocampus) relative to men. The following F values
were obtained: group, F1,43 = 8.17, p = 0.007; sex, F1,43 = 0.30,
p = 0.86; hemisphere, F1,43 = 2.42, p = 0.13; group × hemi-
sphere, F1,43 = 0.01, p = 0.97; group × sex, F1,43 = 0.45, p = 0.50;
sex × hemisphere, F1,43 = 4.47, p = 0.040; group × sex × hemi-
sphere, F1,43 = 0.84, p = 0.36.
The posthoc 2 × 2 (group × sex) ANCOVA confirmed re-
duced left and right hippocampal volumes of GSP patients
(Table 2): left hippocampus, group, F1,43 = 8.08, p = 0.007; sex,
F1,43 = 0.93, p = 0.34; group × sex, F1,43 = 0.10, p = 0.75; right hip-
pocampus, group, F1,43 = 6.39, p = 0.015; sex, F1,43 = 0.31,
p = 0.58; group × sex, F1,43 = 0.82, p = 0.37.
The relation between brain and behaviour 
The volumes of the left- and right-sided amygdala and hip-
pocampus of GSP patients (n = 24) were entered as predictors
into multiple regression analyses (method: stepwise; signifi-
cance level for selecting variables: α = 0.05). Total brain vol-
ume was entered as a further predictor to control for the 
effects of global brain size. Clinical scores (LSAS anxiety
score, LSAS avoidance score, LSAS number of fears, SPAI,
STAI and BDI; Table 1) were used as dependent variables.
When the LSAS scores were considered, right-sided hip-
pocampal volumes significantly predicted the number of so-
cial fears (β = –0.533, p = 0.014), indicating higher scores (i.e.,
stronger disorder severity) in patients with smaller right hip-
pocampal volumes. For the STAI scores, smaller right-sided
amygdalar volumes significantly predicted stronger state
Irle et al.
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Table 1: Clinical and socio-demographic characteristics of patients







Age, yr, mean (SD) [range] 32 (10) [19–49] 31 (9) [19–47]
Education, no. of yr 15 (2) 15 (2)
Sex, male:female, no. 12:12 12:12
Handedness, right:left, no. 23:1 22:2
Duration of disorder, yr 15 (10) –
Age at disorder onset, yr 17 (5) –
DSM-IV diagnoses, no. of patients –
GSP 15 –
GSP, avoidant personality disorder 7 –
GSP, bulimia nervosa 1 –
GSP, panic disorder with agoraphobia 1 –
Liebowitz Social Anxiety Scale17 score –
Anxiety 38 (9) –
Avoidance 29 (9) –
Number of fears 18 (3) –
Social Phobia and Anxiety Inventory19
score†
4 (1) –
State Trait Anxiety Inventory,20 state
anxiety score
45 (10) –
Beck Depression Inventory21 13 (7) –
GSP = generalized social phobia; SD = standard deviation.
*Unless otherwise indicated.
†German version with 22 items (range: 0–6).
Amygdalar and hippocampal size in generalized social phobia
J Psychiatry Neurosci 2010;35(2) 129
anxiety (β = –0.615, p = 0.001). Regression models with the
same predictors and BDI or SPAI as dependent variables
were not significant.
Multiple regression analyses (method: stepwise; signifi-
cance level for selecting variables: α = 0.05) were also per-
formed with the predictors age, age at disorder onset and
disorder duration and left and right amygdalar volume and
left and right hippocampal volume as dependent variables,
respectively. None of the predictors significantly predicted
left or right hippocampal volumes or left amygdalar volumes
of the GSP patients. However, right amygdalar volumes were
significantly predicted by age (β = –0.475, p = 0.019), indicat-
ing smaller volumes in older GSP patients.
Influence of comorbid APD on brain and behaviour
The GSP patients with comorbid APD (n = 7, 5 men) did not
differ significantly from those without APD (n = 17, 7 men) for
left and right hippocampal volume or left and right amygdalar
volume (ANCOVA adjusting for total brain volume). The
overall 2 × 2 × 2 (group × sex × hemisphere) ANCOVA adjust-
ing for total brain volume were repeated for GSP patients
without APD (n = 17) and controls (n = 24). The ANCOVA
comparing amygdalar volumes yielded a significant effect of
group (F1,36 = 6.33, p = 0.017) and group × sex (F1,36 = 10.00,
p = 0.003), indicating that male GSP patients had smaller
amygdalar volumes. The ANCOVA comparing hippocampal
volumes yielded a significant effect of group (F1,36 = 5.47,
p = 0.025), indicating smaller hippocampal volumes in GSP pa-
tients. None of the other terms were statistically significant.
The GSP patients with comorbid APD did not differ signifi-
cantly from those without APD in terms of age, education and
age at disorder onset. However, patients with comorbid APD
had a longer disorder duration (t22 = –2.34, p = 0.029) and
showed stronger anxiety (t22 = –3.63, p = 0.001) and avoidance
(t22 = –4.02, p = 0.001) on the LSAS and had a higher SPAI score
(t22 = –4.13, p < 0.001) than patients without comorbid APD.
Comparisons of the BDI and the STAI score were not significant.
Discussion
To our knowledge, our study is the first structural 3-D MRI
study of social phobia and the first study to investigate
amygdalar and hippocampal size in this disorder. Our results
indicate reduced amygdalar and hippocampal size in indi-
viduals with GSP. None of our patients received psychophar-
macologic or psychotherapeutic treatment at the time of the
assessment. None of our patients had experienced traumatic
exposure, which is associated with amygdalar and hip-
pocampal size reduction.6 We excluded patients with comor-
bid depression because major depressive disorder was
shown to be also related to small hippocampal size.7
We found significant relations between right hippocampal
volume and social phobia severity, indicating smaller vol-
umes in GSP patients with a more generalized disorder. Fur-
thermore, a relation between right amygdalar size and state
anxiety emerged, indicating smaller amygdalar size in pa-
tients with stronger anxiety. Significant negative relations be-
tween hippocampal size and PTSD severity have been well
established.6 There is also evidence that the small hippocam-
pal size of individuals with major depressive disorder is re-
lated to stronger anxiety symptoms.25 Animal experiments
have shown that lesions of the hippocampus destroy the abil-
ity to avoid stressful stimuli.26 Accordingly, recent studies in-
volving healthy individuals suggest that individuals with
small hippocampal and amygdalar size may have deficits in
inhibiting stressful thoughts and feelings.27,28
The mechanisms underlying amygdalar and hippocampal
size reduction in anxiety disorders are not well understood.
Research involving nonhuman primates has suggested that
stress and prolonged glucocorticoid exposure may damage
the hippocampus.9 There is also evidence that hypergluta-
matergic activity may contribute to neural toxicity (i.e., hip-
pocampus degeneration) in individuals who had been ex-
posed to extreme stress.29 Animal studies demonstrated that
activation of N-methyl-D-aspartate glutamate receptors in-
hibits neurogenesis in the hippocampus30 and increases the
excitability of amygdala neurons.31
In contrast, it can be argued that pre-existing small hip-
pocampal and amygdalar size increases the risk of developing
anxiety or affective disorders. A twin study investigating hip-
pocampal size in Vietnam veterans suggested that individuals
with smaller hippocampal size were at greater risk for de -
veloping PTSD,10 rendering it likely that genetic factors con-
tribute to the small hippocampal size of individuals with
PTSD. Polymorphisms in the promoter region of the serotonin
Table 2: Morphometric measures of patients with generalized social phobia and healthy controls
Group; mean (SD)*
Brain volume, mL GSP patients, n = 24 Controls, n = 24 Statistical test p value
Intracranial volume 1552 (139) 1550 (109) t46 = –0.06 0.96
Total brain volume 1225 (119) 1233 (86) t46 = 0.27 0.79
Amygdala
Left 0.96 (0.14) [–17.2] 1.16 (0.20) F1,43 = 13.29 0.001
Right 0.98 (0.19) [–9.3] 1.08 (0.19) F1,43 = 4.20 0.046
Hippocampus
Left 2.79 (0.36) [–7.9] 3.03 (0.26) F1,43 = 8.08 0.007
Right 2.97 (0.36) [–7.8] 3.22 (0.34) F1,43 = 6.39 0.015
GSP = generalized social phobia; SD = standard deviation.
*Values in square brackets indicate the percentage difference in regional volume relative to controls.
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transporter (5-HTTLPR) were shown to influence hippocam-
pal size in individuals with depression11 and to influence the
reactivity of the amygdala of healthy people32 and those with
social phobia33 toward salient environmental cues. A longitu-
dinal study found that genetic variation of the serotonin trans-
porter was associated with the development of depres sion 
following stressful life events, suggesting a gene-by- 
environment interaction in which the response to environmental
insults is moderated by genetic factors.34
There is preliminary evidence of the beneficial effects of
antidepressant pharmacologic treatment on hippocampal
size reduction in mood and anxiety disorders.35,36 Several re-
cent findings suggest that structural magnetic resonance
imaging may also predict response to treatment.37 Results
from our multicentre trial of psychotherapy for social pho-
bia12 will elucidate whether treatment responders have less
decline or even an increase in amygdalar and hippocampal
size when compared with nonresponders and with patients
without treatment (on waiting lists). These forthcoming re-
sults may also provide clues as to whether amygdalar and
hippocampal size reductions in social phobia are related to
environmental influences or predisposition, or both.
Limitations
Our sample included only patients with the generalized sub-
type of social phobia. Furthermore, we excluded patients
with comorbid depressive disorders, because major depres-
sive disorder has been shown to be related to small hip-
pocampal size.7 Thus, our sample may not be considered rep-
resentative. Future studies will show whether individuals
with the nongeneralized subtype of social phobia also have
reduced amygdalar and hippocampal size. Furthermore, it
seems important to compare GSP patients with social phobia
patients with only performance fears, because these sub-
groups may be biologically heterogeneous.38
We found statistically significant amygdalar size reduc-
tions in male but not female GSP patients. However, the
number of male and female GSP patients included were
small. We are not aware of clear sex differences in amygdalar
or hippocampal size reduction in PTSD6 or major depressive
disorder.7,8 However, functional brain imaging has revealed
differential emotion processing between men and women.39
Future studies using larger patient series are needed to clar-
ify whether men with anxiety disorders are more prone to
amygdalar size reduction than women are.
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Canadian College of Neuropsychopharmacology
The Jock Cleghorn Prize
This prize, which is a cheque for $500, will be awarded by the CCNP for the best poster presenta-
tion by a research trainee (graduate student or clinical resident) at the Annual Meeting of the
CCNP. All trainees/students who submit a poster presentation for the Annual Meeting will be el-
igible for this prize. Those already applying for travel bursaries will automatically be considered
for the Jock Cleghorn Prize.
The poster presentations will be judged at the Annual Meeting by a committee consisting of at
least 3 members of the Awards Committee (or substitute judges to be chosen by the Council from
the CCNP membership if Awards Committee members are unable to attend the Annual Meet-
ing). Topics on either basic or clinical aspects of neuropsychopharmacology will be considered.
The poster should represent research in which the graduate student or resident is the primary
 investigator, and (s)he should be the first author of the submitted abstract. The winner of the
award will be announced in the first Newsletter after the Annual Meeting.
